Patient Home
Welcome to Health Vidya. Discover trusted care and your own health — all in one place.
These highlights do not include all the information needed to use EMRELIS safely and effectively. See full prescribing information for EMRELIS. EMRELIS™ (telisotuzumab vedotin-tllv) for injection, for intravenous useInitial U.S. Approval: 2025
Medication labelWhy this: Advisory · dailymed-prescription
EMRELIS is indicated for the treatment of adult patients with locally advanced or metastatic, non-squamous non-small cell lung cancer (NSCLC) with high c-Met protein overexpression [≥50% of tumor cells with strong (3+) staining], as determined by an FDA-approved test [see Dosage and Administration ( 2.1 )], who have received a prior systemic therapy. This indication is approved under accelerated approval based on overall response rate (ORR) and duration of response (DOR) [see Clinical Studies ( 14 )]. Continued approval for this indication may be contingent upon verification and description of clinical benefit in a confirmatory trial(s).
- generic_name
- telisotuzumab vedotin
- product_names
- Telisotuzumab Vedotin
- ndc
- 0074-1044, 0074-1044-01, 0074-1055, 0074-1055-01
- group
- drugs
- license
- us-gov-pd
- attribution
- Courtesy of the National Library of Medicine
- reviewed
- 2026-09-18
- language
- en